We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Emergent Biosolutions Inc | NYSE:EBS | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.88 | 46.81% | 2.76 | 1.995 | 1.87 | 1.94 | 2,810,836 | 01:00:00 |
By Kathryn Hardison
Emergent Biosolutions Inc. said the Food and Drug Administration has issued a warning letter to the company regarding deficiencies it found in a February inspection of its Camden manufacturing facility in Baltimore, Maryland.
The letter warned of issues related to Emergent's practices for aseptic processing and systems for cleaning and maintaining equipment to prevent contamination of drug product, the company said in a Friday filing with the Securities and Exchange Commission.
The FDA also recommended the company review and assess its quality management system and work with a consultant on manufacturing practices.
Emergent said Friday that it has retained a third party for additional review of the facility while it waited for the FDA's response. The company said it has made "significant investment to upgrade (its) physical capabilities."
"This is a process that doesn't happen overnight, but one to which we are committed," Emergent said.
Shares fell 4.8% to $29.01 in after-hours trading.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
August 12, 2022 17:46 ET (21:46 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Emergent Biosolutions Chart |
1 Month Emergent Biosolutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions